GoKawiilFDA to add eye-damage warning label to Ozempic, Wegovy, Zepbound and Mounjaro
The FDA issued a drug safety communication requiring makers of GLP-1 drugs—including Ozempic, Wegovy, Zepbound and Mounjaro—to add a warning about a possible link to NAION, a rare condition that restricts blood flow to the optic nerve and can cause sudden, permanent vision loss. The agency says the exact mechanism is unknown, and the condition's rarity, combined with overlapping risk factors common among GLP-1 users like diabetes and high blood pressure, makes confirming a direct causal link difficult.